1. United States Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Aibotics Inc.

Aibotics Inc.

OOTC:AIBT
0.00
USD
+0.00
(-8.12%)
0.00EPS
409,191.39Market Cap
Aibotics Inc.
OTC:AIBT
(OTC Markets)

Recent

price

0.00

P/E

ratio

- -

div

yld

- -

ROIC.AI

2018
2019
2020
2021
2022
2023
2024
2025
TTM
USD
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
- -
- -
- -
-0.38
-0.18
-0.08
-0.14
-0.01
- -
Basic EPS, GAAP
-0.01
0.01
- -
-0.02
-0.05
-0.01
-0.02
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.05
0.05
- -
- -
-0.06
-0.14
-0.08
-0.01
-0.01
Book Value per Share
0.05
0.05
- -
- -
-0.06
-0.27
-0.12
-0.01
-0.01
Tangible Book Value per Share
13
12
12
13
14
15
13
186
468
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
-84,501.74
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
1
1
1
Depreciation Expense
- -
- -
- -
-5
-3
-1
-2
-2
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
-101,500.27
- -
Profit Margin (%)
1
1
- -
1
- -
-4
-5
-5
-5
Working Capital
- -
- -
- -
1
1
- -
- -
- -
- -
LT Debt
1
1
- -
- -
-1
-2
-3
-4
-5
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
0.74
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1
1
1
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
487
539
682
Market Capitalization
1
1
- -

Working Capital

USD

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
5
5
5
Payables & Accruals
2
2
2
ST Debt
1
1
1
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
-404.4%
16.66%
Free Cash Flow
- -
376.57%
76.9%
Net Income, GAAP
- -
6,386.1%
19.88%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
-0.03
-0.03
-0.06
-0.03
-0.14
2025
-0.01
-0.01
- -
- -
-0.01
2026
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Aibotics Inc. engages in AI-driven robotics and automation solutions focused on transforming industrial, service and hospitality operations through advanced machine learning and robotics platforms. The company develops autonomous and semi-autonomous robotic systems, AI software, and integrated IoT solutions designed to optimize workflows, reduce labor costs, and improve accuracy across multiple sectors. Headquartered in Miami, Florida, Aibotics operates internationally with strategic partnerships and distribution agreements to extend its reach into key markets in the Middle East, the Caribbean and beyond. Founded in 2025, the company emphasizes scalable, end-to-end automation offerings tailored to manufacturing, logistics, retail, healthcare and hospitality customers. Core products and services include AI-enabled service robots and automation platforms; robot hardware integrated with cloud-based AI software; deployment and commissioning services; system integration; remote monitoring and predictive maintenance; and ongoing support, training, and customization. Recent developments include strategic alliances to accelerate international expansion, multi-year distribution partnerships, and new product introductions expanding the flagship robot and automation portfolio across additional verticals and regions. Subsidiaries and affiliate arrangements support regional deployments, local service capabilities, and localized regulatory compliance, reinforcing Aibotics’ stance as a global provider of AI-powered robotic solutions.

Company News

Company News APIChatGPT

  • globenewswire.com

    AIBotics Advances PHILL ROBOT™ Trademark Protection as AI Wellness Platform Moves Toward Commercialization

  • globenewswire.com

    Mycotopia Therapies Inc. Announces Name Change to AIBiotics, Inc. and Symbol Change to AIBT

  • globenewswire.com

    AIBotics Provides 2025 Update; Strengthens Position in AI, Wellness, and Robotics

  • globenewswire.com

    Mycotopia Therapies Acquires AI Robotics Assets with a Total Transaction Value of $9 Million

  • globenewswire.com

    Psytech To Merge With Wesana; Mycotopia Shareholders Will Benefit From The Transactions